No CrossRef data available.
Article contents
An infant case of coronary artery aneurysms with no systemic symptoms after treatment for Kawasaki disease
Published online by Cambridge University Press: 05 November 2024
Abstract
This case is a 4-month-old patient with Kawasaki disease who showed coronary artery lesions after a disease relapse. Following the guidelines from the Randomised Controlled Trial to Assess Immunoglobulin plus Steroid Efficacy, the patient initially saw an improvement in symptoms. However, a relapse occurred despite low levels of C-reactive protein, leading to significant coronary artery growth. Treatment with a third dose of intravenous immunoglobulin and cyclosporine led to a slow reduction in the size of the coronary artery abnormalities. This case highlights the difficulty in monitoring Kawasaki disease progression through clinical symptoms and C-reactive protein levels alone. We also emphasise the necessity of echocardiographic monitoring in patients receiving anti-inflammatory treatments, including steroids, because coronary artery problems can arise or continue without the usual signs of Kawasaki disease or increased C-reactive protein levels.
- Type
- Brief Report
- Information
- Copyright
- © The Author(s), 2024. Published by Cambridge University Press
References
Newburger, JW, Takahashi, M, Burns, JC. Kawasaki disease. J Am Coll Cardiol 2016; 67: 1738–1149.CrossRefGoogle ScholarPubMed
Kobayashi, T, Inoue, Y, Takeuchi, K et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606–2612.CrossRefGoogle ScholarPubMed
Kobayashi, T, Saji, T, Otani, T et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613–1620.CrossRefGoogle ScholarPubMed
Minami, T, Hiroyuki, S, Takashi, T. A case of a boy with Kawasaki disease who developed a coronary artery aneurysm after a low C-reactive protein level in the acute phase of the disease. Prog Med 2003; 23: 1737–1740.Google Scholar
Yoshino, A, Tanaka, R, Takano, T, Oishi, T. Afebrile Kawasaki disease with coronary artery dilatation. Pediatr Int 2017; 59: 375–377.CrossRefGoogle ScholarPubMed
Hamada, H, Suzuki, H, Onouchi, Y et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet 2019; 393: 1128–1137.CrossRefGoogle ScholarPubMed
Tremoulet, AH, Jain, S, Jaggi, P et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014; 383: 1731–1738.CrossRefGoogle ScholarPubMed
Genizi, J, Miron, D, Spiegel, R, Fink, D, Horowitz, Y. Kawasaki disease in very young infants: high prevalence of atypical presentation and coronary arteritis. Clin Pediatr 2003; 42: 263–269.CrossRefGoogle ScholarPubMed
Salgado, AP, Ashouri, N, Berry, EK et al. High risk of coronary artery aneurysms in infants younger than 6 Months of age with Kawasaki disease. J Pediatr 2017; 185: 112–116.e1.CrossRefGoogle ScholarPubMed
Mitsuishi, T, Miyata, K, Ando, A, Sano, K, Takanashi, J, Hamada, H. Characteristic nail lesions in kawasaki disease: case series and literature review. J Dermato 2022; 49: 232–238.CrossRefGoogle ScholarPubMed